Clinical Development Protein Expression Virus 
The Pharma Data
APRIL 26, 2022
About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.
The Pharma Data
JULY 21, 2021
Positive top-line results have already been reported for two Phase 2 clinical trials of VLA15 in over 800 healthy adults. VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. About VLA15.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 13, 2021
CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. TNX-801 , live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox. 175:1091-1101 (1992) 2 Karpusas, M et al., International Immunol. (11):1583
Drug Target Review
MAY 22, 2024
Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1
The Pharma Data
OCTOBER 26, 2020
Based on these promising findings, Transgene intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study as we look to provide a better treatment option for this patient population,” added Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene. 27, 2020 06:30 UTC.
Expert insights. Personalized for you.
52 
Let's personalize your content